Key Takeaways
Peptides are emerging as a hot topic in fitness. They’re marketed as the next big thing for fat loss, muscle recovery and “anti-aging,” often promising faster results with less effort. Read on to learn the truth about peptide-based drugs:
- It is essential to know the difference between peptide-based drugs that are FDA-approved medications and those that are not.
- Two well-known examples of peptide-based medications are semaglutide (Wegovy) and tirzepatide (Zepbound), which are approved for chronic weight management in specific patient populations.
- BPC-157 and TB-500 are peptides popular in the fitness world, but they are not FDA-approved and there is insufficient evidence to conclude that these substances improve recovery of injury outcomes in humans.
- Using substances without information on long-term safety essentially means people are participating in uncontrolled personal experiments—without appropriate monitoring, safety oversight or systematic data collection.
- If a substance is not FDA-approved, not backed by strong human clinical trials, sold online as “research use only” and injected without medical supervision, the risks are real and the benefits are uncertain.
Peptides are emerging as a hot topic in fitness. They’re marketed as the next big thing for fat loss, muscle recovery and “anti-aging,” often promising faster results with less effort.
But here’s the uncomfortable truth: many injectable peptide products being promoted in the fitness world are not approved by the U.S. Food and Drug Administration (FDA), are not supported by strong scientific evidence and, in some cases, may pose serious health risks.
What is a Peptide?
A peptide is a short chain of amino acids, which are the building blocks of protein. Your body naturally produces thousands of peptides, including hormones such as insulin and glucagon-like peptide-1 (GLP-1). Some peptides act like hormones, sending signals that control hunger, growth, sleep or other functions.
Because peptides can influence physiological systems, some have been developed for use as medications. This is where confusion often arises.
Certain peptide-based drugs—such as GLP-1 receptor agonists—are prescribed by physicians and are FDA-approved medications supported by large clinical trials and extensive safety monitoring. Others sold online or through some “wellness clinics” are not FDA-approved, may be marketed as “research chemicals” and often carry labels stating they are not intended for human use. That distinction is critically important.
Peptide-based Medications That Are FDA-Approved
Two well-known examples of peptide-based medications are semaglutide (Wegovy) and tirzepatide (Zepbound), which are approved for chronic weight management in specific patient populations.
Large randomized controlled trials published in the New England Journal of Medicine showed impressive results:
- In the STEP-1 trial, people taking semaglutide lost approximately 15% of their body weight on average over 68 weeks.
- In the SURMOUNT-1 trial, tirzepatide also led to substantial weight loss compared to placebo, with higher doses approaching 20% average weight reduction.
These medications underwent years of research, dose-finding studies and regulatory review, and their safety continues to be monitored after approval.
Importantly, however, these results do not generalize to other peptides that have not undergone similar testing.
Peptides Being Pushed by Fitness Influencers
In fitness circles, you may hear about BPC-157 and TB-500, often promoted for muscle recovery, injury healing or tissue regeneration. BPC-157 is part of a popular trend called the “Wolverine stack,” referencing fictional rapid-healing abilities.
The scientific reality is much more limited:
- These compounds are not FDA-approved for medical use.
- There is little to no high-quality human clinical trial evidence demonstrating effectiveness for musculoskeletal healing or performance enhancement in healthy individuals.
- Much of the positive data comes from animal or laboratory studies, which are useful for hypothesis generation but cannot establish efficacy or safety in humans.
- Many therapies that appear promising in preclinical research ultimately fail when tested in people.
- At present, there is insufficient evidence to conclude that these substances improve recovery of injury outcomes in humans.
Safety Concerns
Another major issue is product quality and regulation. Products sold as research peptides are typically not subject to FDA manufacturing oversight. As a result:
- The labeled dose may be inaccurate.
- The product may contain contaminants or impurities.
- Sterility cannot be assured.
- The vial may not contain the advertised compound at all.
Apart from lack of oversight, risks related to self-injection, such as infection, tissue injury and dosing errors, are also concerns.
Concerns about quality should not be dismissed. Investigations into peptides sold online have identified falsified or substandard products, including products marketed as semaglutide that contained different active ingredients. The FDA has also issued warnings about dosing errors and adverse events associated with improperly prepared or compounded GLP-1 medications.
If quality problems can occur with high-demand prescription medications, the risk may be even greater with unregulated research peptides.
The Long-term Unknowns
One of the largest red flags is what we simply don’t know. For many of these compounds, there are no long-term human safety trials evaluating:
- Cardiovascular risk
- Cancer risk
- Immune effects
- Endocrine disruption
- Fertility outcomes
- Long-term metabolic consequences
Using substances without this information essentially means people are participating in uncontrolled personal experiments—without appropriate monitoring, safety oversight or systematic data collection.
What Happens When You Stop?
Even with FDA-approved medications like semaglutide and tirzepatide, research shows that many people regain weight after stopping treatment. Importantly, this indicates that these drugs don’t “fix” metabolism permanently. If outcomes change after stopping well-studied medications, the effects of unapproved peptides—both benefits and risks—are even more unpredictable.
Why This Matters
Social media influencers often show dramatic transformations and claim that peptides are a “biohacking” effort or “next-level optimization.” But when the goal is health, performance or body composition improvement, the strongest scientific support still points to sustainable behaviors—like those outlined in the ACE 7 Core Drivers of Healthy LivingTM.
It’s also important to acknowledge why people consider these options. Interest in experimental therapies often comes from frustration, not vanity. Chronic pain, slow recovery, persistent fatigue or unresolved health concerns can push people to look for solutions outside of traditional care.
Those challenges are real—and they deserve thoughtful medical evaluation, not shortcuts with uncertain risks and value.
Sometimes progress comes from:
- A different rehabilitation approach
- A consultation with a specialist
- A more comprehensive medical evaluation
- Addressing sleep, nutrition, stress or training load and volume
Exercise and health professionals can best support clients by helping them pursue safe, evidence-based and sustainable strategies, not by chasing unproven interventions.
The Bottom Line
If a substance is not FDA-approved, not backed by strong human clinical trials, sold online as “research use only” and injected without medical supervision, the risks are real and the benefits are uncertain.
Science advances carefully for a reason. Primarily, to protect people. Certain aspects of the fitness and wellness industries move fast because novelty and hype attract attention and sales. Before you inject anything, ask:
- Has this been tested in large human trials?
- Is it FDA-approved for this use?
- Are the long-term risks understood?
- Am I being influenced more by marketing than by data?
If you are not sure if a drug is FDA approved or safe for you it is best to consult your doctor and check the FDA database for drug approval.
If currently unapproved peptides are eventually shown to be safe and effective through rigorous research, their use may become appropriate. But until then, skepticism about gray market peptides isn’t negative. Rather, it’s being a responsible health and exercise professional who follows the evidence.
References
Aronne, L.J. et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. Journal of the American Medical Association, 331, 1, 38–48.
Jastreboff, A.M. et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387, 3, 205–216.
Rubino, D. et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. Journal of the American Medical Association, 325, 14, 1414–1425.
Wilding, J.P.H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384, 11, 989–1002.
